PDS Biotechnology Corp
Close on Oct 19, 2026
- Market cap
- $51.01M
- P/E (TTM)
- –
- Dividend yield
- –
About PDS Biotechnology
Pharmaceutical Preparations, SIC 2834
PDS Biotechnology Corporation is a clinical-stage immunotherapy company that develops targeted cancer and infectious disease immunotherapies. The company designs investigational therapies utilizing its proprietary Versamune T-cell-activating platform, both alone and combined with PDS01ADC, an antibody-drug conjugate fused with interleukin 12. It also develops the Infectimune platform to produce preventive vaccines directed against infectious pathogens. These platforms are engineered to stimulate polyfunctional CD4 helper and CD8 killer T cells, as well as disease-specific neutralizing antibodies, to combat malignancies and infectious agents.
The company operates in the biotechnology and pharmaceutical sector. Its clinical pipeline includes candidates such as PDS0101 and PDS0103, which are evaluated in trials targeting indications including HPV16-positive head and neck squamous cell carcinoma, advanced cervical cancer, and colorectal cancer. PDS Biotechnology Corporation maintains its principal executive offices in Princeton, New Jersey.
Summary of the business section of PDS Biotechnology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PDS Biotechnology Corp
- Headquarters
- Princeton, NJ
- Address
- 303a College Road East 08540
- Phone
- (800) 208-3343
- Website
- www.pdsbiotech.com
- Employees
- 21, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Short Hills, New Jersey
Stock & identifiers
- Ticker
- PDSB
- Exchange
- Nasdaq
- IPO date
- Oct 2, 2015
- Shares outstanding
- 56M, Aug 6, 2026
- Public float
- $60.15M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, May 14, 2019; 1-for-20 reverse, Mar 18, 2019
- SEC CIK
- 1472091
- CUSIP
- 70465T107
- ISIN
- US70465T1079
- LEI
- 5493002KU8ACFTSMC935
- EIN
- 26-4231384
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Frank Bedu-Addo | President/CEO, Director | 866,050 |
| Janetta Trochimiuk | Principal Accounting Officer | 1,124 |
| Stephan Toutain | Chief Operating Officer | – |
| Gregory Conn | Chief Scientific Officer | 115,545 |
| Kirk V. Shepard | Chief Medical Officer | – |
| Lars Boesgaard | Chief Financial Officer | – |
| Spencer D. Brown | Senior VP, General Counsel | – |
| Arnold James Banaag | Director | – |
| Patrick Soon-Shiong | Director | – |
| Kamil Ali-Jackson | Director | 11,764 |
| Ilian Iliev | Director | – |
| Otis W. Brawley | Director | – |
| Gregory Gene Freitag | Director | 61,213 |
| Stephen C. Glover | Director | 78,851 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr.Bedu-Addo | $828.31K | $630.19K | $675.47K | $6 | – |
| FY2024 Dr.Bedu-Addo | $2.26M | -$217.79K | $1.13M | $12 | – |
| FY2023 Dr.Bedu-Addo | $5.01M | -$2.39M | $1.81M | $38 | – |
| FY2022 Dr. Bedu-Addo | $2.30M | $5.45M | $756.42K | $163 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 21 employees, all of whom were full-time employees.”
Corporate history
Events identified from SEC filings